Kiniksa Pharmaceuticals International, plc (KNSA) — SEC Financial Statements & Analysis

Kiniksa Pharmaceuticals International, plc (KNSA) is a pharmaceutical preparations company. Kiniksa Pharmaceuticals International, plc trades on Nasdaq as: KNSA. Kiniksa Pharmaceuticals International, plc (KNSA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-28. Based on that filing, Kiniksa Pharmaceuticals International, plc carries a market cap of $3.68B, a P/E ratio of 50.43x, a P/B ratio of 6.08x, a P/S ratio of 4.89x, an enterprise value of $3.49B, and an EV/EBITDA multiple of 36.82x. On profitability, it posts a gross margin of 89.31%, an operating margin of 12.36%, a net margin of 9.69%, a Return on Equity (ROE) of 13.74%, a Return on Assets (ROA) of 10.26%, and a Return on Invested Capital (ROIC) of 17.35%. Per share, it reports EPS of $0.95, diluted EPS of $0.89, free cash flow per share of $2.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 56.71% year-over-year, net income growth of -531.02% year-over-year, and EPS growth of -509.22% year-over-year. On the balance sheet, it maintains a current ratio of 3.79x, a quick ratio of 3.14x, working capital of $437.56M, a debt-to-equity ratio of 0.36x, a debt ratio of 0.27, free cash flow of $164.23M (TTM), and net debt of $-189.95M. Figures sourced from SEC EDGAR.

Market Cap

$3.68B

P/E TTM

50.43x

EPS TTM

$0.95

P/B TTM

6.08x

ROE TTM

13.74%

ROA TTM

10.26%

Debt To Equity

0.36x

Free Cash Flow TTM

$164.23M

Net Revenue TTM Growth 1Y

56.71%

Data as of 2026-03-31 · Source: SEC EDGAR